Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03981822 · ClinicalTrials.gov registry record · Phase 2
A Placebo-Controlled Study Using VP-102 in the Treatment of External Genital Warts
A Phase 2 study, sponsored by Verrica Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 105
- Enrollment target
NCT03981822 is a Phase 2 study that has completed, run by Verrica Pharmaceuticals. The registered enrollment target is 105 participants.
The verdict
NCT03981822, a Phase 2 study, has completed, sponsored by Verrica Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 105 participants
- Enrollment target
Study Summary
This is a Phase 2, double-blind, placebo-controlled study to determine the dose regimen, safety, tolerability, and efficacy of VP-102 in subjects with External Genital Warts (EGW). This study is divided into two parts (Part A and Part B). Increasing durations of skin exposure to study drug (VP-102 or placebo) will be evaluated in three treatment groups prior to progressing to enrollment in Part B. Part A \& B will enroll a approximately 108 subjects completing 4 treatment applications every 21 days and continuing with follow-up assessments at Day 84, 112 and 147.
Interventions
- COMBINATION_PRODUCT Placebo
- COMBINATION_PRODUCT VP-102 and applicator
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 105 participants |
| Start Date | 2019-06-25 |
| Est. Completion | 2020-07-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03981822
The ClinicalTrials.gov registry entry for NCT03981822 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 105 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Verrica Pharmaceuticals, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03981822 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03981822 about?
NCT03981822 is a clinical study titled "A Placebo-Controlled Study Using VP-102 in the Treatment of External Genital Warts". This is a Phase 2, double-blind, placebo-controlled study to determine the dose regimen, safety, tolerability, and efficacy of VP-102 in subjects with External Genital Warts (EGW). This study is divided into two parts (Part A and Part B). Increasing durations of skin exposure to study drug (VP-102 o...
What is the current status of trial NCT03981822?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 105 participants. The study started on 2019-06-25. Estimated completion is 2020-07-08.
What interventions are being tested in trial NCT03981822?
The interventions under investigation include: Placebo (COMBINATION_PRODUCT), VP-102 and applicator (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT03981822?
This trial is sponsored by Verrica Pharmaceuticals, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.